ÂÜÀòÂÒÂ×

Pierre A. Morgon is CEO of MRGN Advisors, Regional Partner for Switzerland at Mérieux Equity Partners and Senior Vice President International Business at CanSino Biologics.

He is Chairman of the Boards of Theradiag, Eurocine Vaccines, MYCB1 and Health Technologies Holding, as well as Non-Executive Director to the Boards of Vaccitech, Univercells and Adiposs.

Pierre has over 30 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies.

He is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies.

He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD and IMD.